Register Login
Register to leave comments
  • News bot May 4, 2026, 11:06 a.m.

    📋 ADMA BIOLOGICS, INC. (ADMA) - Clinical Trial Update

    Filing Date: 2026-05-04

    Accepted: 2026-05-04 07:05:47

    Event Type: Clinical Trial Update

    Event Details:

    ADMA BIOLOGICS, INC. (ADMA) Announces Clinical Trial Update ADMA BIOLOGICS, INC. (ADMA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: required, earlier
    • Diseases/Conditions: ASCENIV™
    • Collaboration: FDA
      • targeting S. pneumonia. ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products and product candidates. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit. www.admabiologics.com INVESTOR RELATIONS CONTACT: Argot Partners | 212-600-1902

    🔬 Clinical Development Pipeline (ADMA BIOLOGICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Other Other Preclinical Primary Immune Deficiency Disorder ClinicalTrials.gov
    Bivigam Other Phase PHASE4 Humoral Immune Response ClinicalTrials.gov
    RI-002 Other Phase PHASE3 Primary Immune Deficiency Disorder ClinicalTrials.gov
    Asceniv™ Other Phase PHASE4 Primary Immune Deficiency ClinicalTrials.gov
    RI-001 BIOLOGICAL Phase PHASE2 Upper Respiratory Tract Infection ClinicalTrials.gov
    Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%] BIOLOGICAL Phase PHASE3 Primary Immune Deficiency Disorders (PIDD) ClinicalTrials.gov
    Hepatitis C Immune Globulin Intravenous (Human) 5% BIOLOGICAL Phase PHASE2 Sequelae of Viral Hepatitis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ADMA BIOLOGICS, INC.
    • Ticker Symbol: ADMA

Search

News categories